4th Mar 2008 15:25
Hikma Pharmaceuticals Plc04 March 2008 Hikma Pharmaceuticals PLC - Voting Rights and Capital LONDON, 4 March 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) notifiesthe market that as at 29 February 2008 its capital consists of 188,053,607ordinary shares with voting rights. There are no shares held in treasury. The above figure (188,053,607) may be used by shareholders as the denominatorfor the calculations by which they will determine if they are required to notifytheir interest in, or a change to their interest in, Hikma Pharmaceuticals PLCunder the FSA's Disclosure and Transparency Rules. - ENDS - Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company Secretary About HikmaHikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and "Generics".Hikma's operations are based principally in the Middle East and North Africa("MENA") region, where it is a market leader and sells across 17 countries, theUnited States and Europe. In 2006, the Group achieved revenues of $317 million(2005 $262 million) and profit attributable to shareholders was $55 million(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. Fornews and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals